<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Myocardial infarction: ST-segment elevation; Oxygen: myocardial infarction; Aspirin: myocardial infarction; Heparin: myocardial infarction; Nitrates: myocardial infarction; Beta-adrenoceptor blocking drugs: myocardial infarction; ACE inhibitors: myocardial infarction" /><meta name="IX" content="Myocardial infarction: ST-segment elevation; Oxygen: myocardial infarction; Aspirin: myocardial infarction; Heparin: myocardial infarction; Nitrates: myocardial infarction; Beta-adrenoceptor blocking drugs: myocardial infarction; ACE inhibitors: myocardial infarction" /><title>Management of ST-segment elevation myocardial infarction (STEMI): British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="204270.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="204270.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=204270.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="60549.htm">2.10 Stable angina, acute coronary syndromes, and fibrinolysis</a> &gt; <a href="60552.htm">2.10.1 Management of stable angina and acute coronary syndromes</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="204269.htm" title="Previous: Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2813.htm" title="Next: 2.10.2 Fibrinolytic drugs">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_204270">Management of ST-segment elevation myocardial infarction (STEMI)</h1><?highlighter on?><div id="pC" class="jN"><div class="cN"><p>Local guidelines for the management of myocardial
infarction should be followed where they exist</p></div><div id="_204271"><p>These notes give an overview
of the initial and long-term management of myocardial infarction with
ST-segment elevation (STEMI). For advice on the management of non-ST-segment
elevation myocardial infarction (NSTEMI) and unstable angina, see <a title="BNF:topic: Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)" href="204269.htm#_204269">above</a>. The aims of
management of STEMI are to provide supportive care and pain relief,
to promote reperfusion and to reduce mortality. Oxygen, nitrates,
and diamorphine or morphine can provide initial support and pain relief; <span>aspirin</span> and percutaneous coronary intervention or thrombolytics
promote reperfusion; anticoagulants help to reduce re-occlusion and
systemic embolisation; long-term use of <span>aspirin</span>, beta-blockers, ACE inhibitors, and statins help to reduce mortality
further.</p><div class="cAZ"><h2>Initial management</h2> <p class="cAX"><b>Oxygen</b> (<a title=" Oxygen" href="3058.htm#_3058">section 3.6</a>) should be administered if there is evidence of hypoxia, pulmonary
oedema, or continuing myocardial ischaemia; hyperoxia should be avoided
and particular care is required in patients with chronic obstructive
airways disease.</p><p>The pain (and anxiety) of myocardial infarction is managed with
slow intravenous injection of <b>diamorphine</b> or <b>morphine</b> (<a title=" Opioid analgesics" href="3491.htm#_3491">section 4.7.2</a>); an antiemetic such as metoclopramide (or,
if left ventricular function is not compromised, <span>cyclizine</span>) by intravenous injection should also be given (<a title=" Drugs used in nausea and vertigo" href="3398.htm#_3398">section 4.6</a>).</p><p><b>Aspirin</b> (chewed or dispersed in water) is given
for its antiplatelet effect (<a title=" Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>); a dose of 300 mg is suitable. If <span>aspirin</span> is given before arrival at hospital, a note saying that it has been
given should be sent with the patient. <b>Clopidogrel</b>, in a dose of 300 mg (or 600 mg [unlicensed] if used prior to percutaneous
coronary intervention), should also be given (<a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>). <b>Prasugrel</b>, in
a dose of 60 mg, is an alternative to clopidogrel in certain patients
undergoing percutaneous coronary intervention (see <a title="BNF:target-block: nice prasugrel 2009" href="2802.htm#_204276">NICE guidance</a>). <b>Ticagrelor</b>, in a dose of 180 mg, is also an alternative to clopidogrel (see <a title="BNF:target-block: Ticagrelor NICE guidance" href="2802.htm#_218765">NICE guidance</a>).</p><p>Patency of the occluded artery can be restored by percutaneous coronary
intervention or by giving a <b>thrombolytic drug</b> (<a title=" Fibrinolytic drugs" href="2813.htm#_2813">section 2.10.2</a>), unless contra-indicated. Percutaneous coronary
intervention is the preferred method; a <b>glycoprotein IIb/IIIa
inhibitor</b> (<a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>) can be used to reduce the risk
of immediate vascular occlusion in intermediate- and high-risk patients.
Patients undergoing percutaneous coronary intervention should also
receive either unfractionated heparin or a low molecular weight heparin
(e.g. enoxaparin); <b>bivalirudin</b> (<a title="BNF:monograph: BIVALIRUDIN" href="129014.htm#_129014">section 2.8.1</a>) is an alternative to the combination
of a glycoprotein IIb/IIIa inhibitor plus a heparin (see also <a title="BNF:target-block: Bivalirudin NICE guidance" href="69372.htm#_218766">NICE guidance</a>).
In patients who cannot be offered percutaneous coronary intervention
within 90 minutes of diagnosis, a thrombolytic drug should be administered
along with either unfractionated heparin (for maximum 2 days), a low
molecular weight heparin (e.g. enoxaparin), or fondaparinux. See <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="2802.htm#_208000">section 2.9</a> for the
use of antiplatelet drugs in patients undergoing coronary stenting.</p><p>Patients who do not receive reperfusion therapy (with percutaneous
coronary intervention or a thrombolytic) should be treated with either
fondaparinux, enoxaparin, or unfractionated heparin. Prescribers should
consult product literature and local protocols (where they exist)
for details of anticoagulant dose and duration.</p><p><b>Nitrates</b> (<a title=" Nitrates" href="2615.htm#_2615">section
2.6.1</a>) are used to relieve ischaemic pain. If sublingual <span>glyceryl trinitrate</span> is not effective, intravenous <span>glyceryl trinitrate</span> or <span>isosorbide dinitrate</span> is given.</p><p>Early administration of some <b>beta-blockers</b> (<a title=" Beta-adrenoceptor blocking drugs" href="2455.htm#_2455">section 2.4</a>) has been shown to be of benefit
and should be given to patients without contra-indications.</p><p><b>ACE inhibitors</b> (<a title=" Angiotensin-converting enzyme inhibitors" href="2578.htm#_2578">section 2.5.5.1</a>), and
angiotensin-II receptor antagonists (<a title="sub-sub-section: Angiotensin-II receptor antagonists" href="27513.htm#_27513">section 2.5.5.2</a>) if
an ACE inhibitor cannot be used, are also of benefit to patients who
have no contra-indications; in hypertensive and normotensive patients
treatment with an ACE inhibitor, or an angiotensin-II receptor antagonist,
can be started within 24 hours of the myocardial infarction and continued
for at least 5–6 weeks (see below for long-term treatment).</p><p>All patients should be closely monitored for hyperglycaemia;
those with diabetes or raised blood-<span>glucose</span> concentration
should receive <b>insulin</b>.</p></div></div><div id="_60552.1"><div class="cAZ"><h2>Long-term management</h2> <p class="cAX">Long-term management following
STEMI involves the use of several drugs which should ideally be started
before the patient is discharged from hospital.</p><p><b>Aspirin</b> (<a title=" Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>) should be given to all patients, unless contra-indicated,
at a dose of 75 mg daily. The addition of <b>clopidogrel</b> (<a title=" Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>) has been shown to reduce morbidity and mortality.
Prasugrel or ticagrelor are alternatives to clopidogrel in certain
patients (see <a title="BNF:section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>). For those intolerant of clopidogrel,
and who are at low risk of bleeding, the combination of <b>warfarin</b> (<a title="sub-section: Oral anticoagulants" href="2791.htm#_2791">section 2.8.2</a>) and aspirin should be considered.
In those intolerant of both aspirin and clopidogrel, warfarin alone
can be used. Warfarin should be continued for those who are already
being treated for another indication, such as atrial fibrillation,
with the addition of aspirin if there is a low risk of bleeding (see
also <a title="BNF:target-block: Combined anticoagulant and antiplatelet therapy" href="201052.htm#_219198">section 2.8.2</a>).
The combination of aspirin with clopidogrel or warfarin increases
the risk of bleeding. See <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="2802.htm#_208000">section 2.9</a> for details
of antiplatelet drug duration following coronary stenting.</p><p><b>Beta-blockers</b> (<a title=" Beta-adrenoceptor blocking drugs" href="2455.htm#_2455">section 2.4</a>) should be given to all patients
in whom they are not contra-indicated. <span>Acebutolol</span>, metoprolol, propranolol, and timolol are suitable; for patients
with left ventricular dysfunction, <span>carvedilol</span>,
bisoprolol, or long-acting metoprolol may be appropriate (<a title="sub-section: Drugs affecting the renin-angiotensin system" href="27510.htm#_27510">section 2.5.5</a>).</p><p><b>Diltiazem</b> [unlicensed] or <b>verapamil</b> (<a title=" Calcium-channel blockers" href="2616.htm#_2616">section 2.6.2</a>) can be considered if a beta-blocker
cannot be used; however, they are contra-indicated in those with left
ventricular dysfunction. Other calcium-channel blockers have no place
in routine long-term management after a myocardial infarction.</p><p>An <b>ACE inhibitor</b> (<a title=" Angiotensin-converting enzyme inhibitors" href="2578.htm#_2578">section 2.5.5.1</a>) should
be considered for all patients, especially those with evidence of
left ventricular dysfunction. If an ACE inhibitor cannot be used,
an angiotensin-II receptor antagonist may be used for patients with
heart failure. A relatively high dose of either the ACE inhibitor
or angiotensin-II receptor antagonist may be required to produce benefit.</p><p><b>Nitrates</b> (<a title=" Nitrates" href="2615.htm#_2615">section
2.6.1</a>) are used for patients with angina.</p><p><b>Eplerenone</b> (<a title="monograph-family: Aldosterone antagonists" href="2368.htm#_2368">section 2.2.3</a>) is licensed
for use following a myocardial infarction in those with left ventricular
dysfunction and evidence of heart failure.</p><p>For the role of <b>statins</b> in preventing recurrent
cardiovascular events, see <a title=" Lipid-regulating drugs" href="2836.htm#_2836">section 2.12</a>.</p></div></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="204269.htm">Previous: Management of unstable angina and non-ST-segment elevation
myocardial infarction (NSTEMI)</a> | <a class="top" href="204270.htm#">Top</a> | <a accesskey="]" href="2813.htm">Next: 2.10.2 Fibrinolytic drugs</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>